{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:48:11Z","timestamp":1791229691546,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Janssen Research and Development, LLC, Titusville, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40263-020-00699-4","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:03:36Z","timestamp":1580256216000},"page":"299-310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program"],"prefix":"10.1007","volume":"34","author":[{"given":"Teodora","family":"Doherty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Wajs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Melkote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaskaran B.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,29]]},"reference":[{"issue":"10","key":"699_CR1","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","volume":"172","author":"DJ Newport","year":"2015","unstructured":"Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB, APA Council of Research Task Force on Novel Biomarkers and Treatments. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry. 2015;172(10):950\u201366.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"699_CR2","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr","year":"2006","unstructured":"Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856\u201364.","journal-title":"Arch Gen Psychiatry"},{"issue":"10","key":"699_CR3","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","volume":"170","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134\u201342.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"699_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","volume":"75","author":"EJ Daly","year":"2018","unstructured":"Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75(2):139\u201348.","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"699_CR5","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","volume":"22","author":"M Fedgchin","year":"2019","unstructured":"Fedgchin M, Trivedi MH, Daly EJ, Melkote R, Lane R, Lim P, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616\u201330.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"699_CR6","first-page":"428","volume":"176","author":"V Popova","year":"2019","unstructured":"Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, et al. Efficacy and safety of flexibly-dosed esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study. Lancet Psychiatry. 2019;176(6):428\u201338.","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"699_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","volume":"76","author":"EJ Daly","year":"2019","unstructured":"Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. A double-blind, randomized withdrawal, multicenter study of esketamine nasal spray plus an oral antidepressant for relapse prevention in treatment-resistant depression (SUSTAIN-1). JAMA Psychiatry. 2019;76(9):893\u2013903. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1189.","journal-title":"JAMA Psychiatry"},{"key":"699_CR8","doi-asserted-by":"crossref","unstructured":"Wajs E, Aluisio L, Holder R, Daly E, Lane R, Lim P, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: Assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. 2020 (in press).","DOI":"10.4088\/JCP.19m12891"},{"key":"699_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.10.008","author":"R Ochs-Ross","year":"2019","unstructured":"Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Hough D, et al. Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression\u2014TRANSFORM-3. Am J Geriatric Psychiatry. 2019. https:\/\/doi.org\/10.1016\/j.jagp.2019.10.008.","journal-title":"Am J Geriatric Psychiatry"},{"issue":"6","key":"699_CR10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1213\/00000539-196811000-00025","volume":"47","author":"DL Traber","year":"1968","unstructured":"Traber DL, Wilson RD, Priano LL. Differentiation of the cardiovascular effects of CI-581. Anesth Analg. 1968;47(6):769\u201378.","journal-title":"Anesth Analg"},{"key":"699_CR11","volume-title":"Miller\u2019s anesthesia","author":"R Miller","year":"2015","unstructured":"Miller R, Eriksson L, Fleisher L, Wiener-Kronish J, Cohen N, Young W. Miller\u2019s anesthesia. 8th ed. Philadelphia: Elsevier; 2015.","edition":"8"},{"issue":"6","key":"699_CR12","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1213\/00000539-199112000-00022","volume":"73","author":"VC Baum","year":"1991","unstructured":"Baum VC, Tecson ME. Ketamine inhibits transsarcolemmal calcium entry in guinea pig myocardium: direct evidence by single cell voltage clamp. Anesth Analg. 1991;73(6):804\u20137.","journal-title":"Anesth Analg"},{"key":"699_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jad.2018.02.025","volume":"236","author":"P Riva-Posse","year":"2018","unstructured":"Riva-Posse P, Reiff CM, Edwards JA, Job GP, Galendez GC, Garlow SJ, et al. Blood pressure safety of subanesthetic ketamine for depression: a report on 684 infusions. J Affect Disord. 2018;236:291\u20137.","journal-title":"J Affect Disord"},{"issue":"3","key":"699_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4088\/JCP.13m08852","volume":"76","author":"LB Wan","year":"2015","unstructured":"Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76(3):247\u201352.","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"699_CR15","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1176\/appi.ps.201300059","volume":"65","author":"DA Mrazek","year":"2014","unstructured":"Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996\u20132013. Psychiatr Serv. 2014;65(8):977\u201387.","journal-title":"Psychiatr Serv"},{"issue":"6","key":"699_CR16","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1097\/01.psy.0000146294.82810.9c","volume":"66","author":"JP van Melle","year":"2004","unstructured":"van Melle JP, de Jonge P, Spijkerman TA, Tijssen JG, Ormel J, van Veldhuisen DJ, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med. 2004;66(6):814\u201382.","journal-title":"Psychosom Med"},{"issue":"3","key":"699_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0006-3223(03)00111-2","volume":"54","author":"RM Carney","year":"2003","unstructured":"Carney RM, Freeland KE. Depression, mortality, and medical morbidity in patients with coronary heart disease. Biol Psychiatry. 2003;54(3):241\u20137.","journal-title":"Biol Psychiatry"},{"key":"699_CR18","unstructured":"Spravato\u2122 (esketamine) nasal spray prescribing information. Titusville: Janssen Pharmaceutical Companies; 2019."},{"key":"699_CR19","unstructured":"Food and Drug Administration. Guidance for Industry: E14 clinical evaluation of QT\/QTc Interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; October 2005. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm073153.pdf. Accessed 30 Oct 2019."},{"key":"699_CR20","unstructured":"Food and Drug Administration. Guidance for Industry. E14 Clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs\u2014questions and answers (R3); June 2017. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM073161.pdf."},{"issue":"9","key":"699_CR21","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/sj.jhh.1000669","volume":"12","author":"LM Van Bortel","year":"1988","unstructured":"Van Bortel LM, Spek JJ. Influence of aging on arterial compliance. J Hum Hypertens. 1988;12(9):583\u20136.","journal-title":"J Hum Hypertens"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00699-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-020-00699-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00699-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:54:17Z","timestamp":1611795257000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-020-00699-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,29]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["699"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00699-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,29]]},"assertion":[{"value":"29 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The open access fee was paid by Janssen Research & Development, LLC, Titusville, NJ, USA, which also provided funding for the studies reported in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Teodora Doherty, Ewa Wajs, Rama Melkote, and Janice Miller are employees of Janssen Research & Development, LLC and hold company equity. Michael A. Weber is a consultant with Janssen Pharmaceuticals. Jaskaran B. Singh worked on the clinical development program of esketamine for treatment-resistant depression during his employment by Janssen Research & Development, LLC; he is currently employed by Neurocrine Biosciences, San Diego, CA USA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors provided their consent for publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at . As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data"}},{"value":"An Institutional Review Board (IRB) (USA) or Independent Ethics Committee (IEC) (Europe) approved the study protocols and their amendments. All procedures performed in the studies were in accordance with the ethical standards of the IRB\/IEC and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the studies.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}